Almac expands by opening £20m cold chain facility

The global contract pharmaceutical development and manufacturing organisation announces the completion of the investment in Northern Ireland

Almac Group announced the completion of a £20 million investment in its cold chain management capabilities with the opening of a 95,000 sq. ft custom built cold store facility at its global headquarters.

Almac has more than 30 years’ experience in the field of global distribution and management of temperature sensitive drug products and this expansion strengthens its ability to serve to its growing global client base, ensuring efficient delivery of clinical supplies and commercial drug products.

The cold store, which is one of the largest of its kind in Europe, has been purpose built in response to customer requirements, which includes consideration to the rapidly growing area of orphan drug products, changes to regulatory compliance and a more stringent focus on data across the supply chain.

The additional capacity and tailored design also offer clients the opportunity to scale up with Almac as their biologic/biosimilar product portfolio increases.

The new facility complements Almac’s existing global clinical supply and drug product capabilities by boasting more than 3000 pallet spaces including -15 to -25°C storage capacity, additional 2–8°C secondary production rooms, 3PL processing areas and a custom designed clinical labelling suite.

Supplementary office space has also been included to accommodate an additional 100 new employees who will be recruited as a result of the expansion.

Alan Armstrong, CEO of Almac Group, said: “Once again, Almac has set the industry standard with another significant investment in our comprehensive global clinical and commercial supply chain offering. This new facility at our global headquarters expands our cold storage capacity by 300% and our frozen storage capabilities by more than 50%, enabling us to better serve our clients and ultimately patients, worldwide thereby maintaining our position as a global leader in the life sciences sector.”

This news comes just weeks after the company announced a £30 million investment in its new European campus based in Dundalk, Ireland, which will ensure the company meets current and future client needs in the EU marketplace.

This expansion includes a new QC laboratory, packaging facility for commercial drug products and a dedicated 79,000 sq. ft EU Distribution Centre for clinical trial supply, all of which is scheduled to be operationally ready by January 2019.